products bioclinic-naturals probiotic-pro-bb536

Probiotic-Pro BB536®

By : Bioclinic Naturals™

Indications

• Bifidobacterium longum
• High potency: 10 billion cfu (colony forming units) of Bifidobacterium longum BB536 per capsule
• Incredibly shelf stable: over 80% survival rate at 1 year at 25° Celsius
• Does not require refrigeration
• Specially formulated with a unique technology to resist disruption in the acidic
conditions of the stomach and to dissolve smoothly in the non-acidic conditions of
the intestine
• BB536 one of the most studied species in the world
• 70 scientific reports conducted, including 35 human clinical trials

Ingredients

Each Capsule Contains:
BB536® Bifidobacterium longum... 10 billion cfu*
*cfu: colony forming units.
‡Guaranteed 10 billion active cells at the time of manufacture.

Non-medicinal Ingredients:
Microcrystalline cellulose, calcium carbonate, vegetarian capsule (carbohydrate gum [cellulose], purified water, silica), vegetable grade magnesium stearate (lubricant).

Contains no artificial preservatives, colours or sweeteners and no corn, soy or wheat.

Description

Probiotic-Pro BB536 is a high potency probiotic, containing 10 billion cfu (colony forming units) per capsule of the species Bifidobacterium longum BB536, one of the most researched in the world. It is supported by more than 70 scientific reports, including 35 human clinical trials. It is a proprietary strain which has a shelf life remarkably longer and more stable than other probiotic supplements, with a survival rate of over 80% after 1 year at 25° Celsius, over 4-fold higher than other competitive strains.

Isolated from healthy human gastrointestinal (GI) tracts, Bifidobacterium longum has long been recognized to be a beneficial species, constituting over 90% of total GI bacteria in breast-fed infants. It has been shown to have multiple immunomodulating effects, such as increasing the production of secretory IgA and activity of both NK cells and neutrophils, as well as balancing Th1 and Th2 immune activity. It also has been shown to enhance mucosal barrier function in patients with ulcerative colitis, partly by up regulating tight junction molecules. In clinical trials, supplementation with BB536 has been shown to reduce allergic symptoms, decrease influenza infection, lower serum cholesterol levels and improve symptoms of inflammatory bowel disease.

Quantity

60 Vegetarian Capsules

Dose

1–2 capsules 2–3 times daily or as directed by a health care professional.

Potential side effects/Safety

Contraindications: Do not use if you are experiencing nausea, fever, vomiting, bloody diarrhea or severe abdominal pain. Do not use if you have an immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long term corticosteroid treat- ment) without supervision by a health care professional. Contains milk casein. It is not recommended for those with milk or casein allergies. Children over 12 can take half the recommendedRa0dult dose if able to swallow capsules.

Drug Interactions: No known drug interactions exist. Separation by at least 2 hours from antibiotic use may improve the efficacy of Probiotic-Pro BB536.

References

"Show references"

"Hide references"

References:
1.Fumiaki Abe, Hirofumi Miyauchi, Ayako Uchijima, et al. Stability of bifidobacteria in powdered formula. International Journal of Food Science and Technology. 2009,44, 718–724.
2.Roger LC, Costabile A, Holland DT, et al. Examination of faecal Bifidobacterium populations in breast- and formula-fed infants during the first 18 months of life. Microbiology. 2010 Nov;156(Pt 11):3329-41.
3.Iwabuchi N, Takahashi N, Xiao JZ, et al. In vitro Th1 cytokine-independent Th2 suppressive effects of bifidobacteria. Microbiol Immunol. 2007;51(7):649-60.
4.Xiao JZ, Kondo S, Yanagisawa N, et al. Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial. Clin Exp Allergy. 2006 Nov;36(11):1425-35.
5.Akatsu H, Iwabuchi N, Xiao JZ, et al. Clinical Effects of Probiotic Bifidobacterium longum BB536 on Immune Function and Intestinal Microbiota in Elderly Patients Receiving Enteral Tube Feeding. JPEN J Parenter Enteral Nutr. 2012 Nov 27. [Epub ahead of print]
6.Takeda Y, Nakase H, Namba K, et al. Upregulation of T-bet and tight junction molecules by Bifidobactrium longum improves colonic inflammation of ulcerative colitis. Inflamm Bowel Dis. 2009 Nov;15(11):1617-8.
7.Xiao JZ, Kondo S, Yanagisawa N, et al. Clinical efficacy of probiotic Bifidobacterium longum for the treatment of symptoms of Japanese cedar pollen allergy in subjects evaluated in an environmental exposure unit. Allergol Int. 2007 Mar;56(1):67-75.
8.Namba K, Hatano M, Yaeshima T, et al. Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly. Biosci Biotechnol Biochem. 2010;74(5):939-45.
9.Kondo J, Xiao JZ, Shirahata A, et al. Modulatory effects of Bifidobacterium longum BB536 on defecation in elderly patients receiving enteral feeding. World J Gastroenterol. 2013 Apr 14;19(14):2162-70.
10.Odamaki T, Sugahara H, Yonezawa S, et al. Effect of the oral intake of yogurt containing Bifidobacterium longum BB536 on the cell numbers of enterotoxigenic Bacteroides fragilis in microbiota. Anaerobe. 2012 Feb;18(1):14-8.
11.Andrade S, Borges N. Effect of fermented milk containing Lactobacillus acidophilus and Bifidobacterium longum on plasma lipids of women with normal or moderately elevated cholesterol. J Dairy Res. 2009 Nov;76(4):469-74.
12.Clark PA, Martin JH. Selection of bifidobacteria for use as dietary adjuvants in cultured dairy foods: III. Tolerance to stimulated bile concentrations of human small intestines. Cult Dairy Prod J. 1994;29:18–21.

Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.healthydigestionclinic.com © 2015 NDAssist Inc. and/or its affiliates. All rights reserved.